These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
640 related articles for article (PubMed ID: 17456787)
1. Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines. Ling YH; Li T; Yuan Z; Haigentz M; Weber TK; Perez-Soler R Mol Pharmacol; 2007 Aug; 72(2):248-58. PubMed ID: 17456787 [TBL] [Abstract][Full Text] [Related]
2. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. de La Motte Rouge T; Galluzzi L; Olaussen KA; Zermati Y; Tasdemir E; Robert T; Ripoche H; Lazar V; Dessen P; Harper F; Pierron G; Pinna G; Araujo N; Harel-Belan A; Armand JP; Wong TW; Soria JC; Kroemer G Cancer Res; 2007 Jul; 67(13):6253-62. PubMed ID: 17616683 [TBL] [Abstract][Full Text] [Related]
3. The inhibition of activated hepatic stellate cells proliferation by arctigenin through G0/G1 phase cell cycle arrest: persistent p27(Kip1) induction by interfering with PI3K/Akt/FOXO3a signaling pathway. Li A; Wang J; Wu M; Zhang X; Zhang H Eur J Pharmacol; 2015 Jan; 747():71-87. PubMed ID: 25498792 [TBL] [Abstract][Full Text] [Related]
4. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. Di Gennaro E; Barbarino M; Bruzzese F; De Lorenzo S; Caraglia M; Abbruzzese A; Avallone A; Comella P; Caponigro F; Pepe S; Budillon A J Cell Physiol; 2003 Apr; 195(1):139-50. PubMed ID: 12599217 [TBL] [Abstract][Full Text] [Related]
5. Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. Busse D; Doughty RS; Ramsey TT; Russell WE; Price JO; Flanagan WM; Shawver LK; Arteaga CL J Biol Chem; 2000 Mar; 275(10):6987-95. PubMed ID: 10702262 [TBL] [Abstract][Full Text] [Related]
6. p27-Associated G1 arrest induced by hinokitiol in human malignant melanoma cells is mediated via down-regulation of pRb, Skp2 ubiquitin ligase, and impairment of Cdk2 function. Liu S; Yamauchi H Cancer Lett; 2009 Dec; 286(2):240-9. PubMed ID: 19631451 [TBL] [Abstract][Full Text] [Related]
7. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. D'Alessio A; De Luca A; Maiello MR; Lamura L; Rachiglio AM; Napolitano M; Gallo M; Normanno N Breast Cancer Res Treat; 2010 Sep; 123(2):387-96. PubMed ID: 19946741 [TBL] [Abstract][Full Text] [Related]
8. Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells. Serizawa M; Takahashi T; Yamamoto N; Koh Y J Thorac Oncol; 2013 Mar; 8(3):259-69. PubMed ID: 23334091 [TBL] [Abstract][Full Text] [Related]
9. sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1. Pagès P; Benali N; Saint-Laurent N; Estève JP; Schally AV; Tkaczuk J; Vaysse N; Susini C; Buscail L J Biol Chem; 1999 May; 274(21):15186-93. PubMed ID: 10329727 [TBL] [Abstract][Full Text] [Related]
10. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992 [TBL] [Abstract][Full Text] [Related]
11. Panaxydol Derived from Panax ginseng Inhibits G Lee JH; Leem DG; Chung KS; Kim KT; Choi SY; Lee KT Biol Pharm Bull; 2018; 41(11):1701-1707. PubMed ID: 30381670 [TBL] [Abstract][Full Text] [Related]
12. Knockdown of protein tyrosine phosphatase SHP-1 inhibits G1/S progression in prostate cancer cells through the regulation of components of the cell-cycle machinery. Rodríguez-Ubreva FJ; Cariaga-Martinez AE; Cortés MA; Romero-De Pablos M; Ropero S; López-Ruiz P; Colás B Oncogene; 2010 Jan; 29(3):345-55. PubMed ID: 19838216 [TBL] [Abstract][Full Text] [Related]
13. BCR signals target p27(Kip1) and cyclin D2 via the PI3-K signalling pathway to mediate cell cycle arrest and apoptosis of WEHI 231 B cells. Banerji L; Glassford J; Lea NC; Thomas NS; Klaus GG; Lam EW Oncogene; 2001 Nov; 20(50):7352-67. PubMed ID: 11704865 [TBL] [Abstract][Full Text] [Related]
14. Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest. Kriegs M; Gurtner K; Can Y; Brammer I; Rieckmann T; Oertel R; Wysocki M; Dorniok F; Gal A; Grob TJ; Laban S; Kasten-Pisula U; Petersen C; Baumann M; Krause M; Dikomey E Radiother Oncol; 2015 Apr; 115(1):120-7. PubMed ID: 25796091 [TBL] [Abstract][Full Text] [Related]
15. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817 [TBL] [Abstract][Full Text] [Related]
16. A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. Zi X; Grasso AW; Kung HJ; Agarwal R Cancer Res; 1998 May; 58(9):1920-9. PubMed ID: 9581834 [TBL] [Abstract][Full Text] [Related]
18. Anti-epidermal growth factor receptor monoclonal antibody 225 upregulates p27(KIP1) and p15(INK4B) and induces G1 arrest in oral squamous carcinoma cell lines. Kiyota A; Shintani S; Mihara M; Nakahara Y; Ueyama Y; Matsumura T; Tachikawa T; Wong DT Oncology; 2002; 63(1):92-8. PubMed ID: 12187077 [TBL] [Abstract][Full Text] [Related]
19. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Andreu EJ; Lledó E; Poch E; Ivorra C; Albero MP; Martínez-Climent JA; Montiel-Duarte C; Rifón J; Pérez-Calvo J; Arbona C; Prósper F; Pérez-Roger I Cancer Res; 2005 Apr; 65(8):3264-72. PubMed ID: 15833859 [TBL] [Abstract][Full Text] [Related]
20. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway. Leone A; Roca MS; Ciardiello C; Terranova-Barberio M; Vitagliano C; Ciliberto G; Mancini R; Di Gennaro E; Bruzzese F; Budillon A Free Radic Biol Med; 2015 Dec; 89():287-99. PubMed ID: 26409771 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]